Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279054 · ClinicalTrials.gov registry record · Early Phase 1
Decreased Neuraxial Morphine After Cesarean Delivery
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 87
- Enrollment target
NCT04279054: Completed Early Phase 1 study, sponsored by University of Alabama at Birmingham.
NCT04279054 is a Early Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 87 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04279054, a Early Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 50mcg to 150mcg morphine in epidural for the goal of decreasing side effects of medication with lower dose in patients who receive a QL block
Primary Outcome
Incidence of primary outcome surrogate marker by need for medication for pruritus based on verbal complaints from patient (Medication given: Yes or No)
Interventions
- DRUG Morphine Sulfate 150 mcg
- DRUG Morphine Sulfate 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2023-07-05 |
| Phase | Early Phase 1 |
What the finished NCT04279054 record still lists
NCT04279054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 2 interventions - of which Morphine Sulfate 150 mcg is the first listed.
NCT04279054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04279054 about?
NCT04279054 is a clinical study titled "Decreased Neuraxial Morphine After Cesarean Delivery". The purpose of this study is to compare 50mcg to 150mcg morphine in epidural for the goal of decreasing side effects of medication with lower dose in patients who receive a QL block
What is the current status of trial NCT04279054?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 87 participants. The study started on 2020-09-09. Estimated completion is 2023-07-05.
What interventions are being tested in trial NCT04279054?
The interventions under investigation include: Morphine Sulfate 150 mcg (DRUG), Morphine Sulfate 50mcg (DRUG).
Who is sponsoring clinical trial NCT04279054?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04279054's enrollment target sits among peer trials
87 251st of 2000 higher than 1,746 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI